The federal government has officially removed the longstanding requirement for prescribers to hold an X-waiver to prescribe buprenorphine for opioid use disorder (OUD). This move comes after years of gradually loosening restrictions on the drug, which is widely used in medication-assisted treatment (MAT) programs. Behavioral health leaders view the change as a positive development, though its immediate impact may be modest, and there are concerns that it could open pathways to subpar care if not managed carefully. Over the long term, however, this regulatory shift, driven by the X-waiver elimination, could help address one of the most pressing challenges in addiction treatment: encouraging more prescribers to treat patients with OUD and consider addiction medicine as a viable career path.
Before this change, the Drug Enforcement Administration (DEA) required prescribers to obtain a special X-waiver certification to prescribe buprenorphine. This included mandatory training, adherence to patient caps, and compliance with several other restrictions designed to control access to the medication. Providers were initially limited to treating 30 patients in their first year and could increase their capacity only through additional approvals, ultimately reaching a maximum of 275 patients following a 2016 rule change by the Substance Abuse and Mental Health Services Administration (SAMHSA). Despite these regulatory frameworks, opioid overdose deaths climbed dramatically over the years. From 2001 to 2021, opioid-specific overdose deaths increased more than eightfold, totaling over 80,000 deaths in 2021, according to the Centers for Disease Control and Prevention (CDC). The COVID-19 pandemic further exacerbated the crisis, with opioid overdose deaths jumping 54% between March 2020 and March 2022.
The Consolidated Appropriations Act of 2023, an omnibus federal spending bill, officially eliminated the X-waiver. On January 12, 2023, the DEA informed all providers registered to prescribe controlled substances that the X-waiver elimination had ended, while also outlining new training requirements related to treating OUD, effective June 21, 2023. For more than two decades, the X-waiver acted as both an administrative hurdle and a barrier to wider adoption of MAT, limiting the number of providers willing or able to treat OUD patients. The X-waiver elimination represents a significant shift in policy and philosophy surrounding addiction treatment.
Behavioral Health Industry Reacts
The response from the behavioral health sector has been largely positive, though tempered with realism. Steve Priest, CEO and founder of Spero Health, emphasized that the X-waiver elimination will not instantly revolutionize OUD treatment access but does remove a major structural barrier. “This is not some practical and tactical thing that, like magic, is going to increase the number of people in treatment by 400%,” Priest told Behavioral Health Business. “I think it provides the opportunity for a physician or nurse practitioner to have a real practice [in addiction medicine] and to not be restrained. To put it bluntly, getting rid of the X-waiver helps reduce stigma in the medical community.”
Headquartered in Brentwood, Tennessee, Spero Health operates 99 integrated outpatient healthcare locations across Indiana, Kentucky, Ohio, Tennessee, Virginia, and West Virginia. The organization has been at the forefront of MAT delivery, emphasizing the importance of combining medication with psychosocial supports for effective treatment outcomes. Similarly, Dr. Nasser Khan, operations group president for Acadia Healthcare Co. Inc., noted that while the waiver elimination is necessary, he does not expect a dramatic surge in active prescribers overnight. Historical data shows that even among the 101,500 providers holding an X-waiver in 2022, only half actively prescribed buprenorphine, with many treating far fewer patients than their maximum capacity allowed.
Potential Challenges and Concerns
While X-waiver elimination reduces administrative barriers, it also introduces potential risks. Jason Kletter, president of BayMark Health Services, cautions that removing caps could dilute quality standards if providers take on overly large patient panels without adequate behavioral health support. The combination of buprenorphine and psychosocial interventions remains the gold standard in MAT for OUD. Without sufficient therapy and counseling, patients may not achieve optimal outcomes, and the risk of relapse could increase.
Stigma remains a significant barrier. Many primary care physicians have historically been hesitant to treat patients with substance use disorders due to concerns about complex care needs, potential disruptions in their practice, or the stigma of treating “those patients.” Kletter notes, “Getting rid of the rule won’t change doctors’ minds about treating these patients.” While the X-waiver elimination may facilitate prescribing, it cannot instantly transform attitudes or overcome deeply ingrained professional hesitations.
Opportunities for Workforce Development
Beyond immediate access, the X-waiver elimination presents long-term opportunities for workforce development in addiction treatment. Dr. Khan emphasizes that integrating OUD management into medical school curricula and residency programs is critical to building a new generation of providers comfortable treating patients with substance use disorders. “That takes a number of years starting with students and trainees, seeing that flow through,” Khan said. Over time, the combination of fewer administrative barriers and better education could lead to more competent, willing prescribers entering the field.
Dr. Charles Peterson, an addiction medicine specialist at Vituity Family Medicine Center, highlights the symbolic power of the move. By officially removing regulatory skepticism from buprenorphine prescribing, the federal government sends a clear message that MAT should be normalized in primary care settings. Peterson draws parallels to the evolution of chronic disease treatment: just as diabetes and hypertension are now routinely managed by primary care providers rather than specialists, OUD treatment could follow a similar trajectory.
Expanding Access Through Innovative Models
Organizations like Jovive Health, the primary care and urgent care arm of Vituity in Emeryville, California, are already demonstrating how the X-waiver elimination can expand access. In February, Jovive Health launched MAT services for OUD at six clinics, with plans to expand further throughout the year. According to Dr. Peterson, these programs were in development prior to the X-waiver elimination, but the regulatory change makes it simpler to scale MAT services across primary care and urgent care settings. The broader goal is to make OUD treatment as accessible as care for other chronic diseases, delivered where patients already receive routine healthcare services.
A Gradual Cultural Shift
While the immediate impact of X-waiver elimination may be limited, experts agree that it is a necessary step toward normalizing MAT in healthcare. The real power lies in reducing stigma, signaling federal support, and creating a pathway for more providers to consider addiction treatment as a career. Over time, these changes could shift how OUD is treated in the U.S., helping to integrate addiction care into mainstream healthcare and ensuring that more patients receive timely, evidence-based treatment.
Ultimately, the X-waiver elimination is part of a broader effort to address the opioid crisis with practical, sustainable strategies. It is not a silver bullet, but it represents progress toward a healthcare system where MAT is widely accessible, stigma is reduced, and providers are empowered to deliver comprehensive care. Paired with psychosocial interventions, proper training, and cultural acceptance, the removal of the X-waiver has the potential to transform the landscape of addiction treatment over the coming years.
